

Electronic Acknowledgement Receipt

EFS ID:	2725981
Application Number:	10568292
International Application Number:	
Confirmation Number:	3519
Title of Invention:	Trans-1 (6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
First Named Inventor/Applicant Name:	Benny Bang-Andersen
Customer Number:	45821
Filer:	Margaret M. Buck
Filer Authorized By:	
Attorney Docket Number:	463USPCT
Receipt Date:	16-JAN-2008
Filing Date:	14-AUG-2006
Time Stamp:	16:17:11
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement Letter	2008-01-16_SIDS_as_filed.pdf	179993 2f5e312d8dbca4c565e9f506e576b7353e52df	no	2

Warnings:

Information:

2	Information Disclosure Statement (IDS) Filed	2008_01_16_SB08_forms_a s_filed.pdf	1269933 4b547e6dd2d6f5a032210a4ed8c3430 42c5db11	no	3
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
3	Foreign Reference	WO2005016900_A1.pdf	8045128 8004e8028fe632a7e334051300455d01 973074d	no	49
Warnings:					
Information:					
4	Foreign Reference	WO9515299_A1.pdf	2861071 00a1133631c5566f146c8fb97a3bb1 eca3d5b	no	25
Warnings:					
Information:					
5	NPL Documents	Balsara_Psychopharm_1979.pdf	957830 4041a0978a25e0d5e66508af84cd79ef 2f5a158f	no	3
Warnings:					
Information:					
6	NPL Documents	Bertz_Clin_Pharmacokinet_1997.pdf	13643014 1b5a091d8076721e63565652d7f8a0b6 7db5e0	no	49
Warnings:					
Information:					
7	NPL Documents	Carlsson_Am_J_Psych_1978.pdf	3416183 8a03a0e20915455a21119111e1e98a371 a05b1f5c	no	10
Warnings:					
Information:					
8	NPL Documents	Carlsson_J_Cardiovasc_Pharmacol_1990.pdf	3721931 8a51ba12776560ba7da0537e0e0e933ed 294f1055	no	10
Warnings:					
Information:					
9	NPL Documents	Chauret_DMD_2001.pdf	2586820 2b2497190735629681319ea370e765c4 49230341a	no	5
Warnings:					
Information:					
10	NPL Documents	Clark_Org_Lett_1999.pdf	1695583 b14020b6afe40fe1999cfa5c253a387e a3c9e35	no	4

Warnings:					
Information:					
11	NPL Documents	Clark_J_Am_Chem_Soc_1998.pdf	594141 5ec071dc10a995dc110ea32592803592f7a9308ba	no	2
Warnings:					
Information:					
12	NPL Documents	Cossy_Synlett_2003.pdf	685103 3b0a33dc3439b1b495726724ec03d4ed9dc823d	no	3
Warnings:					
Information:					
13	NPL Documents	Darpo_Eur_Heart_J_2001.pdf	2490315 4ee4151235c5ecd285e5b1b9d5f15ab1ab16ee8	no	11
Warnings:					
Information:					
14	NPL Documents	Ereshefsky_J_Clin_Psych_1996.pdf	3797946 411dd879b1cf3d91d6935e4bcb739ebbe6301	no	9
Warnings:					
Information:					
15	NPL Documents	Glassman_Am_J_Psych_2001.pdf	2237765 c55f4d899ef196a9b30a3b7543e599e69f8b1c3	no	9
Warnings:					
Information:					
16	NPL Documents	Gu_J_Med_Chem_2000.pdf	5137421 ddf1d5d9f91ac07b6ec6e22f713c6d600c0d359	no	9
Warnings:					
Information:					
17	NPL Documents	Hyttel_J_Neurochem_1985.pdf	2431137 4cf82122e1ea731c7046167cd8f1cab7a033ee287	no	8
Warnings:					
Information:					
18	NPL Documents	Raehl_Clin_Pharm_1985.pdf	7370490 6bd037eef7a0db060ec9cfeff7d24774707b4e79ba	no	16
Warnings:					
Information:					
19	NPL Documents	Shulman_Can_J_Psych_1997.pdf	2813585 4c6e68b6e65c4138e1c089c2f605630f668750b	no	6

Warnings:					
Information:					
20	NPL Documents	Woosley_Annu_Rev_Pharm acol_1996.pdf	4263023 67baa39a039caad4c3e5393262a85765 4e378ba8	no	22
Warnings:					
Information:					
21	NPL Documents	Yap_Clin_Exp_Allergy_1999 .pdf	4338616 08b20aaf7971e3c37c1404de7ed329144c5 987054	no	10
Warnings:					
Information:					
22	NPL Documents	Yun_J_Org_Chem_2000.pdf	7766315 d849b106782ad76272911c846c7e94e 41e013f8d	no	8
Warnings:					
Information:					
23	NPL Documents	Lin_Pharmacol_Rev_1997_ Part_1_of_2.pdf	12327269 9842112a148f8e17586dfe081c48b2b2 103796a5	no	23
Warnings:					
Information:					
24	NPL Documents	Lin_Pharmacol_Rev_1997_ Part_2_of_2.pdf	15055061 4109b631e90c3a0491770c2d1d2371c 8ed1ed4e9	no	24
Warnings:					
Information:					
25	NPL Documents	Rendic_Drug_Metab_Rev_1 997_Part_1_of_3.pdf	6986140 e1570474610ba10335642c12713351c 7854c1c35	no	50
Warnings:					
Information:					
26	NPL Documents	Rendic_Drug_Metab_Rev_1 997_Part_2_of_3.pdf	8360038 a1dc138c66d5700cd591094c4c2f5d0 29927a0c	no	60
Warnings:					
Information:					
27	NPL Documents	Rendic_Drug_Metab_Rev_1 997_Part_3_of_3.pdf	17003115 6064584d849284a776276410b10b1203 110a0110c	no	59
Warnings:					
Information:					
Total Files Size (in bytes):			142034966		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.